Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Transitional Cell

Explore clinical trials studying Carcinoma, Transitional Cell. Study availability and eligibility vary by location and protocol.

417 public trials 125 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Transitional Cell trial results

Completed

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

NCT04943380

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +13 more
Locations
  • Veterans Medical Research Foundation San Diego, California, United States
  • Bay Pines Veterans Affairs Bay Pines, Florida, United States
  • South Florida Veterans Affairs Miami, Florida, United States
  • James A Haley Veterans' Hospital Tampa, Florida, United States
View Trial Details
Completed

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

NCT04822350

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +13 more
Locations
  • CHU Charles Nicolle Rouen, Haute-normandie, France
  • CHU Nantes Nantes, Pays de la Loire Region, France
  • Centre Hospitalier du Pays d AIX Aix-en-Provence, France
  • CHU Amiens-Picardie Amiens, France
View all 81 locations
View Trial Details
Completed

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

NCT06894771

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +45 more
Locations
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301) Hackensack, New Jersey, United States
  • NEXT Oncology ( Site 0300) San Antonio, Texas, United States
  • Princess Margaret Cancer Center ( Site 0101) Toronto, Ontario, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102) Québec, Quebec, Canada
View Trial Details
Completed

Bristol Bladder Trial

NCT01616875

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +13 more
Locations
  • Bristol Haematology + Oncology Centre, Horfield Road Bristol, United Kingdom
View Trial Details
Completed

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +4 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0016) Gilbert, Arizona, United States
  • Community Cancer Institute ( Site 0777) Clovis, California, United States
  • University of California Irvine Medical Center ( Site 0078) Orange, California, United States
  • John Wayne Cancer Institute ( Site 0017) Santa Monica, California, United States
View all 194 locations
View Trial Details
Completed

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

NCT02989064

Conditions
Bladder Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +20 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Washington University - School of Medicine St Louis, Missouri, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Ohio State University Wexner Medical Center Columbus, Ohio, United States
View Trial Details
Completed

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

NCT03869190

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • UCLA Department of Medicine Los Angeles, California, United States
  • UCSF Comprehensive Cancer Ctr San Francisco, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • University of Kentucky Chandler Medical Center Lexington, Kentucky, United States
View all 33 locations
View Trial Details

Related conditions